Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Inclusion Criteria: * Is a pediatric subject requiring anticoagulant therapy * Will abstain from the use of nonsteroidal anti-inflammatory drugs (such as ibuprofen), and other antiplatelet and anticoagulant agents (except for aspirin) from 24 hours prior to edoxaban dose until after the last PK sample is collected * Will follow food and concomitant medication restrictions Exclusion Criteria: * Any major or clinically relevant unexplained bleeding during prior anticoagulant therapy * History of abnormal bleeding or coagulation within last 6 months prior to study drug administration * Renal function with glomerular filtration rate (GFR) less than 50% of normal for age and size * Malabsorption disorders (e.g., cystic fibrosis or short bowel syndrome) * Hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk, alanine transaminase (ALT) \> 5 times the upper limit of normal (ULN) or total bilirubin \> 2 times the ULN with direct bilirubin \> 20% of the total